We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Lucid Diagnostics Inc (LUCD) NPV

Sell:$0.79 Buy:$0.85 Change: $0.0027 (0.35%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.85
Change: $0.0027 (0.35%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$0.79
Buy:$0.85
Change: $0.0027 (0.35%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

Contact details

Address:
360 Madison Avenue, 25Th Floor
NEW YORK
10017
United States
Telephone:
+1 (212) 9494319
Website:
https://www.luciddx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LUCD
ISIN:
US54948X1090
Market cap:
$45.36 million
Shares in issue:
59.34 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lishan Aklog
    Chairman of the Board, Chief Executive Officer
  • Shaun O'Neil
    President, Chief Operating Officer
  • Stanley Lapidus
    Vice Chairman of the Board
  • Dennis Mcgrath
    Chief Financial Officer
  • Michael Gordon
    General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.